$和黄医药(00013)$

和黄医药将于美国临床肿瘤学会 (ASCO) 2024年年会公布数据

和黄医药官微 2024-05-24 08:40 中国香港

中国香港、上海和美国新泽西州：2024年5月24日，星期五：和黄医药(中国)有限公司 (简称 "和黄医药" 或 "HUTCHMED") (纳斯达克/伦敦证交所: HCM; 香港交易所: 13) 今日宣布将于2024年5月31日至6月4日在美国伊利诺伊州芝加哥召开的美国临床肿瘤学会 ("ASCO") 2024年年会上公布和黄医药自主研发的化合物的数项研究的最新及更新后的数据。

标题：呋喹替尼联合信迪利单抗治疗伴有 pMMR 状态的晚期子宫内膜癌患者: 多中心、单臂 II 期研究结果

Fruquintinib Plus Sintilimab in Treated Advanced Endometrial Cancer (EMC) Patients (Pts) with pMMR Status: Results From A Multicenter, Single-Arm Phase 2 Study

标题：呋喹替尼治疗转移性结直肠癌患者中难治性患者根据既往治疗顺序分组: FRESCO 和 FRESCO-2研究的结果

Efficacy and safety of fruquintinib in patients with metastatic colorectal cancer according to prior treatment sequence in the refractory setting: Results from FRESCO and FRESCO-2

标题：呋喹替尼用于治疗难治性转移性结直肠癌

Fruquintinib in Refractory Metastatic Colorectal Cancer

标题：摘要 438730的进一步更新: 呋喹替尼联合紫杉醇对比紫杉醇用于二线治疗晚期胃或胃食管结合部腺癌患者 (FRUTIGA研究): 一项随机、多中心、双盲、安慰剂对照的III期研究

Updates on Abstract 438730: Fruquintinib Plus Paclitaxel Versus Paclitaxel as Second-Line Therapy for Patients with Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (FRUTIGA): A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Phase 3 Study

标题：索凡替尼联合 PD-1/L1 抑制剂作为铂类化疗联合PD-1/L1 抑制剂一线治疗后广泛期小细胞肺癌患者的维持治疗

Surufatinib plus PD-1/L1 inhibitors as maintenance therapy following first line (1L) platinum-based chemotherapy combined with PD-1/L1 inhibitors in patients (pts) with extensive-stage small cell lung cancer (ES-SCLC)

标题：ERK1/2 抑制剂HMPL-295治疗晚期实体瘤患者的首次人体临床试验: 单药疗法的剂量递增结果

First-in-human study of HMPL-295, an ERK1/2 inhibitor, in patients with advanced solid tumors: dose-escalation results of monotherapy

标题：立体定向消融放射治疗联合呋喹替尼和替雷利珠单抗用于治疗转移性结直肠癌: 单臂前瞻性 II 期临床试验 (RIFLE研究) 的最新发现

Stereotactic ablative radiotherapy combined with fruquintinib and tislelizumab in metastatic colorectal cancer: updated findings from a single-arm, prospective phase II trial (RIFLE)

标题：呋喹替尼对比呋喹替尼联合 PD-1 抑制剂用于治疗微卫星稳定型 (MSS) 转移性结直肠癌的倾向性评分匹配比较: 真实世界数据

A propensity score matched comparison of fruquintinib (FRU) versus FRU combined with PD-1 inhibitors for microsatellite stability (MSS) metastatic colorectal cancer: real-world data

标题：肝动脉灌注化疗 (HAIC) 联合呋喹替尼用于三线治疗不可切除或难治性结直肠癌肝转移的 Ib/II 期研究

Phase Ib/II trial of hepatic arterial infusion chemotherapy (HAIC) in combination with fruquintinib as third-line therapy for refractory unresectable colorectal cancer liver metastases

标题：呋喹替尼联合曲氟尿苷/替匹嘧啶 (TAS-102) 用于三线治疗转移性结直肠癌患者的疗效和安全性: 一项单臂、多中心II期研究的结果

Efficacy and safety of fruquintinib plus trifluridine/tipiracil (TAS-102) as third-line treatment in patients with metastatic colorectal adenocarcinoma: Results from a single arm, phase 2, multicenter study

标题：评估呋喹替尼联合替雷利珠单抗及肝动脉灌注化疗 (HAIC) 用于治疗晚期结直肠癌肝转移的有效性和安全性的 II 期研究: 更新后的生存分析

A phase II study to evaluate the efficacy and safety of fruquintinib combined with tislelizumab and Hepatic arteryinfusion chemotherapy (HAIC) for advanced colorectal cancer liver metastases: An updated analysis of survival

标题：呋喹替尼联合信迪利单抗和 SOX用于作为不可切除的局部晚期或转移性胃/胃食管结合部腺癌的转化治疗: 一项单臂、开放标签的II期临床试验

Fruquintinib combined with sintilimab and SOX as conversion therapy for unresectable locally advanced or metastatic gastric/gastroesophageal junction adenocarcinoma (GC/GEJC): A single-arm, open-label, phase 2 clinical trial

标题：短程放疗 (SCRT) 序贯呋喹替尼联合阿德贝利单抗和 CAPOX 作为局部晚期直肠癌的全程新辅助治疗: 一项多中心、单臂、开放标签的 II 期研究

Short-course radiotherapy (SCRT) followed by fruquintinib plus adebrelimab and CAPOX in the total neoadjuvant therapy of locally advanced rectal cancer (LARC): a multicenter, single-arm, open-label, phase II study

标题：呋喹替尼联合卡培他滨对比卡培他滨作为转移性结直肠癌一线维持治疗: 随机对照的Ib/II 期研究的更新结果

Fruquintinib plus capecitabine versus capecitabine as first-line maintenance treatment of metastatic colorectal cancer (mCRC): Update results from the randomized controlled, phase Ib/II study

标题：呋喹替尼联合研究者选择的化疗用于二线治疗转移性结直肠癌的疗效和安全性: 一项多中心、单臂、II期研究的最新结果

Efficacy and safety of fruquintinib plus investigator's choice of chemotherapy as second-line therapy in metastatic colorectal cancer: updated results of a multicenter, single-arm, phase 2 trial

标题：呋喹替尼联合化疗对比标准治疗用于一线治疗晚期转移性结直肠癌的比较分析: 一项与倾向性评分匹配 (PSM) 队列进行比较的前瞻性队列研究

Comparative analysis of first-line therapy with fruquintinib plus chemotherapy versus standard therapy in advanced metastatic colorectal cancer (mCRC): A prospective cohort study compared with propensity score matching (PSM) cohort

标题：以呋喹替尼为基础的疗法用于治疗对多种 TKI 耐药后的难治性骨和软组织肉瘤患者的疗效和安全性: 一项多中心回顾性研究

Efficacy and safety of fruquintinib-based treatment in patients with refractory bone and soft tissue sarcomas after developing resistance to several TKIs: A multi-centered retrospective study

标题：维迪西妥单抗联合呋喹替尼用于治疗对至少两种标准方案耐药的 HER2 表达或 HER2 突变/扩增的转移性结直肠癌患者: 一项前瞻性、探索性的单臂研究

Disitamab vedotin combined with fruquintinib in patients with HER2-expressing or HER2 mutation/amplified metastatic colorectal cancer refractory to at least two standard regimens: A prospective, exploratory, single-arm study

标题：索凡替尼联合TAS-102 用于三线或后线治疗转移性胰腺癌 (mPDAC) 患者: 一项开放标签、单臂的II 期研究

Surufatinib combined with TAS-102 in third- or later-line therapy of patients with metastatic pancreatic cancer (mPDAC): an open-Label, single-Arm, phase II Study

标题：索凡替尼单药或与长春瑞滨的联合疗法作为难治性晚期非小细胞肺癌患者的后线治疗

Surufatinib monotherapy or combined with vinorelbine as a late-line therapy in patients with refractory advanced non–small cell lung cancer (NSCLC)

标题：索凡替尼联合卡瑞利珠单抗和化疗治疗晚期结直肠癌的 Ib/II 期研究的最新疗效和安全性结果

Updated efficacy and safety results from the phase Ib/II study of surufatinib combined with camrelizumab and chemotherapy in patients with advanced colorectal cancer

标题：评估索凡替尼治疗标准化疗失败的骨肉瘤和软组织肉瘤患者的 II 期研究: 更新分析结果

Phase II study to evaluate surufatinib in patients with osteosarcoma and soft tissue sarcoma who have failed in standard chemotherapy: updated analysis

标题：索凡替尼联合EP方案和斯鲁利单抗用于一线治疗神经内分泌癌的疗效和安全性

Efficacy and safety of Surufatinib combined with EP regimen and Serplulimab in first-line treatment of NEC

标题：索凡替尼治疗晚期神经内分泌肿瘤的表现: 来自真实世界研究的观点

Performance of surufatinib in treating advanced neuroendocrine neoplasms: Insights from a real-world study

标题：肿瘤伴神经内分泌分化的流行病学调查: 重点关注胰腺和胆管癌队列

Epidemiological investigation of neuroendocrine differentiation in carcinomas: Focus on pancreatic and cholangiocarcinoma cohorts

标题：索凡替尼、特瑞普利单抗、白蛋白结合型紫杉醇联合放射治疗或手术用于一线治疗食管鳞状细胞癌的疗效和安全性: 一项单中心前瞻性临床试验

Efficacy and safety of surufatinib, toripalimab, nab-paclitaxel in combination with radiotherapy or surgery in the first-line treatment of esophageal squamous cell cancer: A single-centered prospective clinical trial

标题：索凡替尼用于二线治疗对安罗替尼耐药、放射性碘难治性的分化型甲状腺癌的疗效和安全性: 一项探索性的多中心研究

Efficacy and safety of second-line treatment with surufatinib for anlotinib-resistant radioiodine-refractory differentiated thyroid cancer: An exploratory multicenter study